c-Kit (Y823D)

KIT · Variant type: point · HGVS: p.Y823D

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ripretinib	99.6%	0.4%	92.95
2	Avapritinib	99.5%	0.5%	97.73
3	Sorafenib	99.4%	0.6%	96.72
4	Pralsetinib	99.1%	0.9%	93.43
5	Tivozanib	99.1%	0.9%	92.42
6	Pacritinib	99.0%	1.0%	88.64
7	Lenvatinib	98.9%	1.1%	97.74
8	Dasatinib	98.7%	1.3%	87.97
9	Ponatinib	98.7%	1.3%	78.23
10	Pazopanib	98.5%	1.5%	97.49
11	Regorafenib	98.4%	1.6%	95.99
12	Nintedanib	98.4%	1.6%	90.23
13	Erdafitinib	98.4%	1.6%	95.71
14	Vemurafenib	98.1%	1.9%	96.49
15	Axitinib	97.9%	2.1%	93.23
16	Apatinib	97.8%	2.2%	97.73
17	Nilotinib	97.7%	2.3%	96.49
18	Cabozantinib	97.3%	2.7%	92.73
19	Fostamatinib	96.6%	3.4%	96.74
20	Brigatinib	95.9%	4.1%	82.96
21	Selpercatinib	95.6%	4.4%	96.72
22	Quizartinib	95.0%	5.0%	99.50
23	Umbralisib	94.0%	6.0%	98.74
24	Fedratinib	92.0%	8.0%	96.21
25	Sunitinib	90.9%	9.1%	91.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ripretinib	99.6%	—	—
Avapritinib	99.5%	—	—
Sorafenib	99.4%	—	—
Pralsetinib	99.1%	—	—
Tivozanib	99.1%	—	—
Pacritinib	99.0%	—	—
Lenvatinib	98.9%	—	—
Dasatinib	98.7%	—	—
Ponatinib	98.7%	—	—
Pazopanib	98.5%	—	—
Regorafenib	98.4%	—	—
Nintedanib	98.4%	—	—
Erdafitinib	98.4%	—	—
Vemurafenib	98.1%	—	—
Axitinib	97.9%	—	—
Apatinib	97.8%	—	—
Nilotinib	97.7%	—	—
Cabozantinib	97.3%	—	—
Fostamatinib	96.6%	—	—
Brigatinib	95.9%	—	—
Selpercatinib	95.6%	—	—
Quizartinib	95.0%	—	—
Umbralisib	94.0%	—	—
Fedratinib	92.0%	—	—
Sunitinib	90.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms